1-7 of 7
Yelena Kovtun, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Pre-Clinical Efficacy of CD123-Targeting Antibody-Drug Conjugate IMGN632 in Blastic Plasmacytoid Dentritic Cell Neoplasm (BPDCN) Models

Qi Zhang, PhD, Tianyu Cai, PhD, Lina Han, PhD, Vinitha Mary Kuruvilla, Sharlene Adams, PhD, Sloss M Callum, Karine Harutyunyan, PhD, Andrew A. Lane, MD PhD, Yelena Kovtun, PhD, Naval G. Daver, MD, Naveen Pemmaraju, MD, Patrick Zweider McKay, MD PhD, Marina Y. Konopleva, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3956.
https://doi.org/10.1182/blood-2018-99-116771
Published: 2018
Journal Articles

Synergistic Anti-Leukemic Activity of PARP Inhibition Combined with IMGN632, an Anti-CD123 Antibody-Drug Conjugate in Acute Myeloid Leukemia Models

Claire Fritz, Scott M. Portwood, MS, MBA, Julie Adams, BS, Tara Cronin, BA, Linda Lutgen-Dunckley, Brandon L Martens, BS, Callum M. Sloss, PhD, Krystal Watkins, Yelena Kovtun, PhD, Sharlene Adams, PhD, Eunice S. Wang, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2647.
https://doi.org/10.1182/blood-2018-99-117214
Published: 2018
Journal Articles

CD123 Expression Patterns and Potential of IMGN632, a CD123-Targeted Antibody Drug Conjugate, in Acute Lymphoblastic Leukemia

Evgeniya Angelova, MD PhD, Charlene Audette, Yelena Kovtun, PhD, Naval Daver, MD, Sa A. Wang, MD, Sherry Pierce, BSN, BA, Sergej Naumovich Konoplev, MD PhD, Jeffrey L. Jorgensen, MD PhD, Marina Konopleva, MD PhD, Patrick A. Zweidler-McKay, MDPhD, Hagop M. Kantarjian, MD, Elias J. Jabbour, MD, Joseph David Khoury, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2718.
https://doi.org/10.1182/blood.V130.Suppl_1.2718.2718
Published: 2017
Journal Articles

IMGN632: A CD123-Targeting Antibody-Drug Conjugate (ADC) with a Novel DNA-Alkylating Payload, Is Highly Active and Prolongs Survival in Acute Myeloid Leukemia (AML) Xenograft Models

Sharlene Adams, PhD, Alan Wilhelm, Lauren Harvey, MS, Chen Bai, Nicholas Yoder, PhD, Yelena Kovtun, PhD, Thomas Chittenden, PhD, Jan Pinkas, PhD
Journal: Blood
Blood (2016) 128 (22): 2832.
https://doi.org/10.1182/blood.V128.22.2832.2832
Published: 2016
Journal Articles

A CD123-Targeting Antibody-Drug Conjugate (ADC), IMGN632, Designed to Eradicate Acute Myeloid Leukemia (AML) Cells While Sparing Normal Bone Marrow Cells

Yelena Kovtun, PhD, Gregory Jones, Charlene Audette, Lauren Harvey, MS, Baudouin Gerard, PhD, Alan Wilhelm, Chen Bai, Sharlene Adams, PhD, Victor S Goldmacher, PhD, Ravi Chari, PhD, Thomas Chittenden, PhD
Journal: Blood
Blood (2016) 128 (22): 768.
https://doi.org/10.1182/blood.V128.22.768.768
Published: 2016
Journal Articles

IMGN779, a CD33-Targeted Antibody-Drug Conjugate (ADC) with a Novel DNA-Alkylating Effector Molecule, Induces DNA Damage, Cell Cycle Arrest, and Apoptosis in AML Cells

Watkins M Krystal, MS, Russell Walker, MS, Nathan Fishkin, PhD, Charlene Audette, Yelena Kovtun, PhD, Angela Romanelli, PhD
Journal: Blood
Blood (2015) 126 (23): 1366.
https://doi.org/10.1182/blood.V126.23.1366.1366
Published: 2015
Journal Articles

The Antibody-Drug Conjugate (ADC) IMGN779 Is Highly Active in Vitro and in Vivo Against Acute Myeloid Leukemia (AML) with FLT3-ITD Mutations

Kathleen R Whiteman, MS, Paul Noordhuis, PhD, Russell Walker, MS, Krystal Watkins, MS, Yelena Kovtun, PhD, Lauren Harvey, BS, Alan Wilhelm, BS, Holly Johnson, BS, Gerrit Jan Schuurhuis, PhD, Gert J Ossenkoppele, MD PhD, Robert J. Lutz, PhD
Journal: Blood
Blood (2014) 124 (21): 2321.
https://doi.org/10.1182/blood.V124.21.2321.2321
Published: 2014